Evidence map›Paper›PMID 33716483›Full record

ArticleFederal practitioner : for the health care professionals of the VA, DoD, and PHS2021

Guideline Concordance With Durvalumab in Unresectable Stage III Non-Small Cell Lung Cancer: A Single Center Veterans Hospital Experience.

Nabiel A Mir, Olivia Hull, Sheneka Bothwell, Devika Das

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Federal practitioner : for the health care professionals of the VA, DoD, and PHS, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Nabiel A Miris a Clinical Nurse Educator, and is the Section Chief of Oncology, both at Birmingham Veterans Affairs Medical Center in Alabama. was an Internal Medicine Resident in the Department of Medicine at the time the article was written; is a Fellow in the Division of Hematology and Oncology, and Devika Das is Clinical Assistant Professor of Hematology and Oncology, all at University of Alabama at Birmingham.
Olivia Hullis a Clinical Nurse Educator, and is the Section Chief of Oncology, both at Birmingham Veterans Affairs Medical Center in Alabama. was an Internal Medicine Resident in the Department of Medicine at the time the article was written; is a Fellow in the Division of Hematology and Oncology, and Devika Das is Clinical Assistant Professor of Hematology and Oncology, all at University of Alabama at Birmingham.
Sheneka Bothwellis a Clinical Nurse Educator, and is the Section Chief of Oncology, both at Birmingham Veterans Affairs Medical Center in Alabama. was an Internal Medicine Resident in the Department of Medicine at the time the article was written; is a Fellow in the Division of Hematology and Oncology, and Devika Das is Clinical Assistant Professor of Hematology and Oncology, all at University of Alabama at Birmingham.
Devika Dasis a Clinical Nurse Educator, and is the Section Chief of Oncology, both at Birmingham Veterans Affairs Medical Center in Alabama. was an Internal Medicine Resident in the Department of Medicine at the time the article was written; is a Fellow in the Division of Hematology and Oncology, and Devika Das is Clinical Assistant Professor of Hematology and Oncology, all at University of Alabama at Birmingham.
University of Alabama at Birmingham · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDurvalumab is recommended by national guidelines for patients with unresectable stage III non-small cell lung cancer (NSCLC) following concurrent chemoradiation therapy (CRT). Nonadherence to guidelines is associated with adverse outcomes. We studied the adherence and identified barriers to durvalumab usage at the Birmingham Veterans Affairs Medical Center (VAMC) Oncology Clinic in Alabama.

methodsUsing retrospective analysis, we assessed the use of consolidative durvalumab among veterans at Birmingham VAMC. The health records of all veterans with stage III unresectable NSCLC from October 2017 to August 2019 were reviewed. Data collected included demographics, barriers to CRT initiation and completion, durvalumab usage, and reasons for not prescribing durvalumab.

resultsIn our data review, 34 patients were found to have stage III unresectable NSCLC. Twenty (58.8%) of those 34 initiated CRT, but only 16 (47.1%) completed CRT treatment and 7 (20.6%) underwent further treatment with durvalumab. Of the 14 patients who did not initiate CRT, the most common reasons were poor performance status and/or the presence of comorbidities. Of the evaluable cohort of 34, 11 (32.4%) patients with stage III NSCLC received durvalumab. Of the 9 eligible patients who did not receive durvalumab, the most common reasons cited were toxicities experienced during or following CRT (11.8%).

conclusionsJust one-third of patients were eligible to receive durvalumab at Birmingham VAMC. This was likely due to the difference between clinical trial and real-world patient populations. Interventions to address socioeconomic and system level barriers to improve our center's delivery of lung cancer treatment are planned.

Identifiers

PMID33716483
PMCPMC7953853
OpenAlexW3107501938

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.